Therapeutic potential of green tea in nonalcoholic fatty liver disease

被引:95
|
作者
Masterjohn, Christopher [1 ]
Bruno, Richard S. [1 ]
机构
[1] Univ Connecticut, Dept Nutr Sci, Storrs, CT 06269 USA
关键词
catechins; green tea; hepatic steatosis; nonalcoholic steatohepatitis; oxidative stress; NF-KAPPA-B; ELEMENT-BINDING PROTEIN-1C; CHOLINE-DEFICIENT DIET; GROWTH-FACTOR RECEPTOR; EPIGALLOCATECHIN GALLATE; HEPATIC STEATOSIS; (-)-EPIGALLOCATECHIN GALLATE; INSULIN-RESISTANCE; POLYPHENOL EPIGALLOCATECHIN-3-GALLATE; GLUCOSE-UPTAKE;
D O I
10.1111/j.1753-4887.2011.00440.x
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Nonalcoholic fatty liver disease (NAFLD) is a constellation of progressive liver disorders that are closely related to obesity, diabetes, and insulin resistance and may afflict over 70 million Americans. NAFLD may occur as relatively benign, nonprogressive liver steatosis, but in many individuals it may progress in severity to nonalcoholic steatohepatitis, fibrosis, cirrhosis, and liver failure or hepatocellular carcinoma. No validated treatments currently exist for NAFLD except for weight loss, which has a poor long-term success rate. Thus, dietary strategies that prevent the development of liver steatosis or its progression to nonalcoholic steatohepatitis are critically needed. Green tea is rich in polyphenolic catechins that have hypolipidemic, thermogenic, antioxidant, and anti-inflammatory activities that may mitigate the occurrence and progression of NAFLD. This review presents the experimental evidence demonstrating the hepatoprotective properties of green tea and its catechins and the proposed mechanisms by which these targeted dietary agents protect against NAFLD.
引用
收藏
页码:41 / 56
页数:16
相关论文
共 50 条
  • [1] Hepatoprotective activities of green tea in nonalcoholic fatty liver disease
    Park, Hea Jin
    Bruno, Richard S.
    [J]. AGRO FOOD INDUSTRY HI-TECH, 2010, 21 (01): : 37 - 40
  • [2] Therapeutic Effects of Green Tea on Nonalcoholic Fatty Liver Disease in 10-16-Year-Old Children
    Rostampour, Noushin
    Kasiri, Karam Ali
    Hashemi-Dehkordi, Elham
    Taheri, Abdol Majid
    Broujeni, Anahita Farahzad
    Rafieian-Kopaei, Mahmoud
    [J]. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2019, 13 (07) : BC4 - BC7
  • [3] Preventive Efficiency of Green Tea and Its Components on Nonalcoholic Fatty Liver Disease
    Zhou, Jie
    Ho, Chi-Tang
    Long, Piaopiao
    Meng, Qilu
    Zhang, Liang
    Wan, Xiaochun
    [J]. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2019, 67 (19) : 5306 - 5317
  • [4] The Effect of Green Tea Extract Supplementation on Liver Enzymes in Patients with Nonalcoholic Fatty Liver Disease
    Pezeshki, Ali
    Safi, Sara
    Feizi, Awat
    Askari, Gholamreza
    Karami, Fatemeh
    [J]. INTERNATIONAL JOURNAL OF PREVENTIVE MEDICINE, 2016, 7 : 1 - 6
  • [5] Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implications
    Vachliotis, Ilias D.
    Anastasilakis, Athanasios D.
    Goulas, Antonis
    Goulis, Dimitrios G.
    Polyzos, Stergios A.
    [J]. DIABETES OBESITY & METABOLISM, 2022, 24 (09): : 1702 - 1720
  • [6] Targeting lipophagy as a potential therapeutic strategy for nonalcoholic fatty liver disease
    Li, Hong-Ying
    Peng, Zong-Gen
    [J]. BIOCHEMICAL PHARMACOLOGY, 2022, 197
  • [7] Therapeutic Potential of Nicotinamide Adenine Dinucleotide for Nonalcoholic Fatty Liver Disease
    Gual, Philippe
    Postic, Catherine
    [J]. HEPATOLOGY, 2016, 63 (04) : 1074 - 1077
  • [8] Lipophagy: A potential therapeutic target for nonalcoholic and alcoholic fatty liver disease
    Han, Ying-Hao
    He, Xin-Mei
    Jin, Mei-Hua
    Sun, Hu-Nan
    Kwon, Taeho
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2023, 672 : 36 - 44
  • [9] The endoplasmic reticulum as a potential therapeutic target in nonalcoholic fatty liver disease
    Gentile, Christopher L.
    Pagliassotti, Michael J.
    [J]. CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2008, 9 (10) : 1084 - 1088
  • [10] Therapeutic options in nonalcoholic fatty liver disease
    Jeffrey L. Tokar
    Carl L. Berg
    [J]. Current Treatment Options in Gastroenterology, 2002, 5 (6) : 425 - 436